» Articles » PMID: 19461900

Tiotropium Bromide: an Update

Overview
Publisher Bentham Open
Specialty Pulmonary Medicine
Date 2009 May 23
PMID 19461900
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes such as significant improvements in spirometry, hyperinflation, dyspnea, heath status, acute exacerbations and mortality have been consistently observed in tiotropium clinical trials, and the drug has been shown to reduce the risk of mortality due to cardiac-vascular disease and respiratory failure. The main side effect reported is dryness of the mouth. Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the beta2-adrenergic receptor and those with a high percentage of neutrophils in sputum.

Citing Articles

Future perspectives of anticholinergics for the treatment of asthma in adults and children.

Buhl R, Hamelmann E Ther Clin Risk Manag. 2019; 15:473-485.

PMID: 30936709 PMC: 6422409. DOI: 10.2147/TCRM.S180890.


Bronchodilator Effect of Tiotropium via RespimatAdministered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD).

Ogasawara T, Sakata J, Aoshima Y, Tanaka K, Yano T, Kasamatsu N Intern Med. 2017; 56(18):2401-2406.

PMID: 28824055 PMC: 5643165. DOI: 10.2169/internalmedicine.8255-16.


Effect of inhaled drugs on anxiety and depression in patients with chronic obstructive pulmonary disease: a prospective observational study.

Hyun M, Lee N, Jang E, Yim J, Lee C Int J Chron Obstruct Pulmon Dis. 2016; 11:747-54.

PMID: 27114705 PMC: 4833365. DOI: 10.2147/COPD.S96969.

References
1.
Wise R, Connett J, Weinmann G, Scanlon P, Skeans M . Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2001; 343(26):1902-9. DOI: 10.1056/NEJM200012283432601. View

2.
Calverley P, Lee A, Towse L, van Noord J, Witek T, Kelsen S . Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003; 58(10):855-60. PMC: 1746483. DOI: 10.1136/thorax.58.10.855. View

3.
Celli B, Thomas N, Anderson J, Ferguson G, Jenkins C, Jones P . Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008; 178(4):332-8. DOI: 10.1164/rccm.200712-1869OC. View

4.
Taube C, Lehnigk B, Paasch K, Kirsten D, Jorres R, Magnussen H . Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 162(1):216-20. DOI: 10.1164/ajrccm.162.1.9909054. View

5.
van Noord J, Aumann J, Janssens E, Verhaert J, Smeets J, Mueller A . Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006; 129(3):509-17. DOI: 10.1378/chest.129.3.509. View